1. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder
- Author
-
Simoons, M. (Mirjam), Mulder, H. (Hans), Appeldoorn, J.T.Y. (Jerôme T Y), Risselada, A.J. (Arne), Schene, A.H. (Aart), Schaik, R.H.N. (Ron) van, Roon, E.N. (Eric) van, Ruhé, E.G. (Eric G.), Simoons, M. (Mirjam), Mulder, H. (Hans), Appeldoorn, J.T.Y. (Jerôme T Y), Risselada, A.J. (Arne), Schene, A.H. (Aart), Schaik, R.H.N. (Ron) van, Roon, E.N. (Eric) van, and Ruhé, E.G. (Eric G.) more...
- Abstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) exert substantial variability in effectiveness in patients with major depressive disorder (MDD), with up to 50-60% not achieving adequate response. Elucidating pharmacokinetic factors that explain this variability is important to increase treatment effectiveness. OBJECTIVES: To examine potential modification of the relationship between paroxetine serum concentration (PSC) and serotonin transporter (SERT)-occupancy by single nucleotide polymorphisms (SNPs) of the ABCB1 gene, coding for the P-glycoprotein (P-gp) pump, in MDD patients. To investigate the relationship between ABCB1 SNPs and clinical response. METHODS: Patients had MDD and received paroxetine 20 mg/day. We measured PSC after 6 weeks. We quantified SERT-occupancy with SPECT imaging (n = 38) and measured 17-item Hamilton Depression Rating Scale (HDRS17)-scores at baseline and after 6 week more...
- Published
- 2020
- Full Text
- View/download PDF